Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

BACKGROUND: The sodium–glucose cotransporter-2 (SGLT2) inhibitor canagliflozin has been shown to reduce major cardiovascular events in type 2 diabetic patients, with a pronounced decrease in hospitalization for heart failure (HF) especially in those with HF at baseline. These might indicate a potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayour, Alex Ali, Korkmaz-Icöz, Sevil, Loganathan, Sivakkanan, Ruppert, Mihály, Sayour, Viktor Nabil, Oláh, Attila, Benke, Kálmán, Brune, Maik, Benkő, Rita, Horváth, Eszter Mária, Karck, Matthias, Merkely, Béla, Radovits, Tamás, Szabó, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469222/
https://www.ncbi.nlm.nih.gov/pubmed/30992077
http://dx.doi.org/10.1186/s12967-019-1881-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469222/
https://www.ncbi.nlm.nih.gov/pubmed/30992077
http://dx.doi.org/10.1186/s12967-019-1881-8

Ejemplares similares